Tulio Rodriguez, M.D.
- Hematologic Malignancies
- Blood and Bone Marrow Transplantation
- Multiple Myeloma
- Director, Hematology, Bone Marrow Transplant and Cellular Therapy Program, City of Hope Cancer Center Chicago
- Professor, Department of Hematology & Hematopoietic Cell Transplantation
- Referring Physicians Phone(847) 746-9990
- Referring Physicians Fax(847) 342-4089
- Referring Physicians Email[email protected]
Tulio Rodriguez, M.D., joined City of Hope® Cancer Center Chicago in September 2023 as a hematologic oncologist and the director of the Hematology, Bone Marrow Transplant and Cellular Therapy Program. Dr. Rodriguez cares for patients at City of Hope Cancer Care Downtown Chicago and its Chicago-area hospital in Zion, Illinois. He specializes in the treatment of blood cancers such as lymphoma, leukemia and myeloma . Board certified in hematology by the American Board of Internal Medicine and bilingual in English and Spanish, Dr. Rodriguez brings with him over 20 years of experience in hematologic malignancies and bone marrow transplantation and has performed over 2,500 transplant procedures during his career.
After earning his medical degree from Pontificia Universidad Católica Madre y Maestra School of Medicine in Santiago, Dominican Republic, Dr. Rodriguez did his internal medicine residency at San Juan Veterans Affairs Medical Center in San Juan, Puerto Rico, then completed fellowships in hematology/oncology and bone marrow transplantation at the University of Texas Health Science Center in San Antonio, Texas.
At City of Hope, Dr. Rodriguez serves as the Clinical Professor for the Department of Hematology & Hematopoietic Cell Transplantation and is also a professor of medicine at Rosalind Franklin University of Medicine and Science in Chicago. He is passionate about working with local Latino populations to advocate for awareness of and screening for blood cancers.
Dr. Rodriguez has an extensive research background. He has regularly served as a guest lecturer on innovations in hematology and has earned numerous awards for his research, including the Leukemia Research Foundation’s Hero of Hope Award and the American Cancer Society’s Clinical Oncology Fellowship Award. In 2024, he was named one of Crain’s Notable Leaders in Healthcare for expanding City of Hope Chicago’s bone marrow transplantation and hematology programs to bring innovative treatment options such as CAR T cell therapy to more patients across the state and beyond.
Location
Chicago Cancer Center
Zion, IL 60099
Downtown Chicago Cancer Care
Chicago, IL 60611
Education & Experience
- American Board of Internal Medicine (ABIM)
- Pontificia Universidad Católica Madre y Maestra School of Medicine, Santiago, Dominican Republic
- Internal Medicine, San Juan Veterans Affairs Medical Center, San Juan, Puerto Rico
- Hematology/Oncology, University of Texas Health Science Center, San Antonio, Texas
- Bone Marrow Transplantation, The University of Texas Health Science Center at San Antonio, San Antonio, Texas
Publications
- Shaughnessy, P. J., Ornstein, D., Ririe, D., Callander, N., Anderson, J. E., Pollack, M.S., Freytes, C. O., J. Cruz. Rodriguez T, Bachier, C., LeMaistre, C. F., Phase 2 study of a moderate-intensity preparative regimen with allogeneic peripheral blood stem cell transplantation for hematologic diseases: the Texas Transplant Consortium experience. Biol Blood Marrow Transplant. 2002;8(8):420-8.
- Rodriguez TE, Stiff PJ. Current treatment results of allogeneic bone marrow transplantation for acute myeloid and lymphoid leukemia. Curr Hematol Rep. 2003 Jul;2(4):295-30I. Review Article
- Toor, AA.; Ayers, J; Strupeck, J; Parthasarathy, M; Creech, S: Rodriguez, T.; Stiff, P. J. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol. 2004;124(6):769-76.
- Duns JE, Stiff PJ, Choi J, Parthasarathy M. Rodriguez T, Toor AA. Second allografts for relapsed hematologic malignancies: feasibility of using a different donor. Bone Marrow Transplant. 2005 Feb;35(3):26 l-4.
- Stiff, PJ, Miller, L. A., Mumby, P., Kiley, K, Batiste, R., Porter, N., Potocki, K., Volle, M., Lichtenstein, S., Wojtowicz, S., Zakrzewski, S., Toor, A0 Rodriguez, T, Patients' understanding of disease status and treatment plan at initial hematopoietic stem cell transplantation consultation. Bone Marrow Transplant. 2006; 1-6. January 23rd.
- Stiff P, Mumby P, Miler L, Rodriguez T, Parthswarthy M, Kiley K, Porter N, Batiste R, Wojtowitz S, Lichtenstein S, Fox-Geiman M, Toor A. Autologous Hematopoietic Stem Cell Transplants that Utilize Total Body Irradiation Can Safely be Carried Out Entirely on an Outpatient Basis. Bone Marrow Transplant. 2006 Dec; 38(11):757-64.
- Smith, S. E., Toor, A., Rodriguez. T., Stiff, P. The administration of polymerized human hemoglobin (Pyridoxylated) to a Jehovah's Witness after submyeloablative stem cell transplantation complicated by delayed graft failure. Compr Ther. 2006 Fall;32(3 ):172-5.
- Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A, Molina A, Smith D, Ivers B, Kogut N, Popplewell L, Rodriguez R, Somlo G, Forman SJ, Nademanee A. Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma. Biol Blood Marrow Transplant. 2007May;13(5):594-600. Epub 2007 Mar 23
- Toor, AA, Stiff, PJ, Nickoloff, BJ. Rodriguez T., Klein, J., Gordon, K.B. Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity, J Dermatolog Treat. 2007;18(1):13-8.
- Mullane, K., Toor, A. A., Kalnicky, C. Rodriguez T., Klein, J., Stiff, P. Posaconazole Salvage Therapy Allows Successful Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory Invasive Mold Infections. Transpl Infect Dis. 2007 Jun;9(2):89-96.